Branded tirzepatide self-pay prices sit far below the shortage-era gap

A price index covering 14 telehealth providers put the median first-month price for compounded semaglutide at $197 and for compounded tirzepatide at $299 as of September 3, 2026 ^[3]. Brand list prices before any membership fee were higher: the Wegovy pen ran $199 to $349 and Zepbound $299 to $449 ^[3][1]. Mounjaro, the diabetes version of tirzepatide, listed at a flat $499 a month across all doses through LillyDirect ^[2].

The gap shows up inside subscription programs too. Noom's brand-medication track was priced at $39 for the first month and then $129 a month, while WW Med+ offered $25 a month for an introductory period before rising to $74, with medication billed separately in both cases ^[3]. Noom also sold its own compounded tirzepatide at $149 for month one and $299 after, alongside a compounded semaglutide option and a microdose semaglutide track ^[3]. WeightWatchers, by contrast, carries no compounded product on its menu; it dropped compounded semaglutide around May 2025, a few months after the FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025 ^[3].

That timing matters because the shortage declarations were the main legal basis compounding pharmacies had relied on to make copies of patented drugs. Once FDA lifted the shortage designations, that footing mostly went away, yet compounded sellers kept operating, and the price data suggest a straightforward reason: compounded tirzepatide and semaglutide still cost noticeably less than the brand-name pens even before factoring in program membership fees ^[3].

The FDA has logged adverse-event reports tied to compounded products: 990 for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 ^[3]. Regulatory action has also touched specific sellers. Medvi received an FDA warning letter in February 2026, and AltRx's parent company, Trinity Healthcare Supply, received one in June 2026; Henry Meds faces active, unresolved litigation from Eli Lilly over how it marketed compounded tirzepatide ^[4]. An independent scoring site that rates telehealth GLP-1 providers gives lower marks to compounded-primary sellers partly because no major clinical trial tested a compounded formulation, and partly for regulatory issues like these ^[4].

Why it matters for patients

For someone paying cash, the numbers translate directly into a monthly budget decision. A patient choosing the starting dose of Zepbound through LillyDirect pays $299 a month before any telehealth membership fee ^[1], while a median compounded tirzepatide option runs about $299 as well by the index, though some providers price lower ^[3]. Brand medications carry FDA review of manufacturing, safety, and effectiveness that compounded versions do not ^[4]. Compounded versions are prepared by pharmacies rather than the original manufacturer and are not individually FDA-reviewed ^[4]. The price gap is real, but it sits alongside a documented count of adverse-event reports and, for some sellers, active regulatory warnings or litigation ^[3][4]. Coverage also differs sharply by channel: WeightWatchers' insurance coordination applies to commercial plans, not Medicare, Medicaid, or Kaiser, according to third-party reporting on its program ^[3].

What happens next

Some self-pay brand offers are time-limited. The Wegovy pen's $199 introductory price for new patients was set to run only through December 31, 2026, before rising to $349 ^[3]. WW's $25-a-month introductory Med+ rate was scheduled to end September 8, 2026 ^[3]. Prices, provider lineups, and any further FDA warning letters can change and should be confirmed directly with each company before enrolling.